The Ipamorelin + CJC-1295 (No DAC) pairing is a well-known experimental combination used to model growth hormone release through two distinct physiological pathways. This dual-receptor approach allows researchers to explore pulsatile GH dynamics in controlled laboratory systems.
Ipamorelin is a selective ghrelin-receptor (GHS-R1a) agonist studied for its ability to trigger calcium-dependent GH release. Its hormonal selectivity makes it a valuable tool for examining pituitary GH output without substantial cross-activation of other endocrine axes.
CJC-1295 (No DAC) is a short-acting GHRH analog designed to mimic physiologic GHRH signaling rather than extended hormone exposure. In research models, it activates the GHRH receptor and increases cAMP-driven transcriptional and secretory GH pathways.
Together, these compounds are used to study how ghrelin-based and GHRH-based signals converge within somatotrophs. This pairing also enables investigation into the relative contributions of pulse amplitude, pulse frequency, and downstream IGF-axis modulation under experimental conditions.
The combination is frequently referenced in research involving pituitary responsiveness, GH-receptor signaling efficiency, and feedback interactions involving somatostatin. Because the two peptides operate through independent receptors, the pairing allows for a comprehensive examination of multi-pathway GH control.
No validated pharmacokinetic or synergistic clinical data exist for this combination, and all interactions remain theoretical and model-dependent. Findings observed with this pairing should not be extrapolated beyond controlled laboratory environments.
This research bundle is intended exclusively for scientific exploration of GH secretion pathways, receptor biology, and endocrine signal integration. For laboratory research use only, not for human or veterinary use.
